Chemical Engineering @ChemengFiles.Com

Dr. Willmar Schwabe Pharmaceuticals has bought the company Peithner Dr. Wiener Holding GmbH. This acquisition will enable Schwabe increase its presence in Austria and in Central and Eastern Europe (ECE).

Dr. Dirk Reischig, chairman of the board and CEO of Dr. Willmar Schwabe Pharmaceuticals, said: "We are delighted that the group of companies Peithner joins Schwabe.

Dr. Willmar Schwabe Pharmaceuticals has bought the company Peithner Dr. Wiener Holding GmbH. This acquisition will enable Schwabe increase its presence in Austria and in Central and Eastern Europe (ECE).

Dr. Dirk Reischig, chairman of the board and CEO of Dr. Willmar Schwabe Pharmaceuticals, said: "We are delighted that the group of companies Peithner joins Schwabe.

The biomarkers are increasingly important in research of Alzheimer's disease as a method for risk assessment, primary screening, testing of new therapies and eventual primary intervention with better drugs when they develop. As part of its ongoing investigation and development of biomarkers for Alzheimer's and other diseases, BARC Central Laboratory is pleased to announce that it has joined the panel of inquiry into the Alzheimer's Association. As a sponsor, BARC will participate in the presentations of the panel and the subcommittee meetings related, focusing in particular on the evolution of biochemical biomarkers as indicators of prognosis and diagnosis.

It is believed that the high level changes cerebraldel Alzheimer's disease, including amyloid plaques and neurofibrillary tangles, begin many years before symptoms are evident or there is a death of brain cells. It is vital to identify those affected while still normal in terms of cognitive, so future therapies for modifying the disease can preserve normal functions. Testing and eventual use of these therapies require the identification of persons affected and "at risk" in order to bring them to clinical trials and direct and control therapies.

"Alzheimer's disease is undoubtedly a growing epidemic and a leading concern in public health. The Alzheimer's Association is the leading voluntary health organization in the U.S. research community is dedicated to eradicating Alzheimer enfermedaddel, BARC and aims to advance in the detection and primary tratamientodel Alzheimeren association with the Alzheimer's Association and other member of the panel of inquiry, "said Rudi Marien, CEO of BARC Group.

The biomarkers are increasingly important in research of Alzheimer's disease as a method for risk assessment, primary screening, testing of new therapies and eventual primary intervention with better drugs when they develop. As part of its ongoing investigation and development of biomarkers for Alzheimer's and other diseases, BARC Central Laboratory is pleased to announce that it has joined the panel of inquiry into the Alzheimer's Association. As a sponsor, BARC will participate in the presentations of the panel and the subcommittee meetings related, focusing in particular on the evolution of biochemical biomarkers as indicators of prognosis and diagnosis.

It is believed that the high level changes cerebraldel Alzheimer's disease, including amyloid plaques and neurofibrillary tangles, begin many years before symptoms are evident or there is a death of brain cells. It is vital to identify those affected while still normal in terms of cognitive, so future therapies for modifying the disease can preserve normal functions. Testing and eventual use of these therapies require the identification of persons affected and "at risk" in order to bring them to clinical trials and direct and control therapies.

"Alzheimer's disease is undoubtedly a growing epidemic and a leading concern in public health. The Alzheimer's Association is the leading voluntary health organization in the U.S. research community is dedicated to eradicating Alzheimer enfermedaddel, BARC and aims to advance in the detection and primary tratamientodel Alzheimeren association with the Alzheimer's Association and other member of the panel of inquiry, "said Rudi Marien, CEO of BARC Group.

Afton Chemical Corporation announced its two new research and development facilities in Asia-Pacific. A new facility in Shanghai, China, will open in early 2009 and a new, expanded facility in Tsukuba, Japan, started its operations recently. The main objectives of these laboratories are to improve the response time to customers and develop more products for the specific needs of the Asia-Pacific region.

R & D facility in Shanghai is located in the Zizhu Science Industrial Park and provides a space of more than 1,000 square meters including nine fully equipped laboratories for analytical development and testing. The facility is located in the vicinity of two leading universities.

Afton Chemical Corporation announced its two new research and development facilities in Asia-Pacific. A new facility in Shanghai, China, will open in early 2009 and a new, expanded facility in Tsukuba, Japan, started its operations recently. The main objectives of these laboratories are to improve the response time to customers and develop more products for the specific needs of the Asia-Pacific region.

R & D facility in Shanghai is located in the Zizhu Science Industrial Park and provides a space of more than 1,000 square meters including nine fully equipped laboratories for analytical development and testing. The facility is located in the vicinity of two leading universities.